The growing popularity of GLP-1 medications for weight management has created an unexpected procedural safety concern that could affect millions of users undergoing routine medical examinations. These drugs fundamentally alter gastric emptying patterns, potentially creating complications during diagnostic procedures that require an empty stomach. The randomized clinical trial examined patients taking semaglutide, liraglutide, and dual GLP-1/GIP receptor agonists who continued their medications before upper endoscopy procedures. Results showed a statistically significant increase in clinically meaningful residual gastric volume compared to patients who had discontinued these medications prior to the procedure. The effect was most pronounced with longer-acting formulations and higher doses. This finding challenges current pre-procedural protocols that may not adequately account for the gastric motility effects of these increasingly prescribed medications. The safety implications extend beyond endoscopy to any procedure requiring sedation where aspiration risk must be minimized, including certain surgeries and diagnostic imaging with contrast. For the estimated 15 million Americans now taking GLP-1 medications, this represents a paradigm shift in pre-procedural planning. The research suggests medical teams may need to extend fasting periods or modify protocols when patients are taking these agents. However, the study's relatively small sample size and focus on a single procedure type limits broader generalization. The findings appear confirmatory of known GLP-1 gastric effects rather than revealing entirely new mechanisms, but they provide the first controlled evidence of procedural risk. As GLP-1 use continues expanding, particularly among older adults who frequently require endoscopic procedures, establishing evidence-based discontinuation guidelines becomes increasingly critical for patient safety.